We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Transcription Regulation Depends on Release from Chromatin

By LabMedica International staff writers
Posted on 09 May 2018
Print article
Image: The long non-coding RNA called A-ROD is only functional the moment it is released from chromatin into the nucleoplasm. At this transient phase, it can bring transcription factors to specific sites in DNA to enhance gene expression. After its complete release from chromatin, A-ROD is no longer active (Photo courtesy of Evgenia Ntini, Max Planck Institute for Molecular Genetics).
Image: The long non-coding RNA called A-ROD is only functional the moment it is released from chromatin into the nucleoplasm. At this transient phase, it can bring transcription factors to specific sites in DNA to enhance gene expression. After its complete release from chromatin, A-ROD is no longer active (Photo courtesy of Evgenia Ntini, Max Planck Institute for Molecular Genetics).
A team of German genome researchers has demonstrated that release from chromatin is a crucial functional aspect of long noncoding RNAs in transcription regulation of their target genes.

Long non-coding RNAs (lncRNAs) are considered to be non-protein coding transcripts longer than 200 nucleotides. This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study. Their name notwithstanding, long non-coding RNAs (lncRNAs) have been found to actually encode synthesis of small polypeptides that can fine-tune the activity of critical cellular components. LncRNAs are often enriched in the nucleus and at chromatin, but whether their dissociation from chromatin is important for their role in transcription regulation is unclear.

To better understand the link between lncRNAs and chromatin, investigators at the Max Planck Institute for Molecular Genetics (Berlin, Germany) grouped lncRNAs using epigenetic marks, expression, and strength of chromosomal interactions.

They reported in the April 24, 2018, online edition of the journal Nature Communications that lncRNAs transcribed from loci engaged in strong long-range chromosomal interactions were less abundant at chromatin, suggesting the release from chromatin was a crucial functional aspect of lncRNAs in transcription regulation of their target genes.

To gain mechanistic insight into this mechanism, they functionally validated the lncRNA A-ROD, which enhances DKK1 (Dickkopf-related protein 1) transcription via its nascent spliced released form. Detailed validation provided evidence that the regulatory effect was exerted by A-ROD at its release from the chromatin-associated site of transcription.

These findings provide evidence that the regulatory interaction required dissociation of A-ROD from chromatin, with target specificity having been established during the period of chromosomal proximity.

Related Links:
Max Planck Institute for Molecular Genetics

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.